Image Of Namenda Chemical Structure (74ce605d B493 4b95 9d59 9253f81f4e20 01)
Namenda
Product Images NDC 21695-232
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Namenda (NDC 21695-232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Of Figure 1: Time Course Of Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 02)
Image Of Figure 2: Cumalative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 03)
The text is a graph displaying the cumulative percentage of patients on Placebo and NAMENDA, with respect to their ADCS-ADL change from baseline. The x-axis displays the change from the baseline (from -5 to 25), while the y-axis displays the cumulative percentage of patients.*
Image Of Figure 3: Time Course Of The Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 04)
The text refers to a graph or table representing the SIB score, a measurement of cognitive function, and the mean change from baseline after treatment with either placebo or Namenda over a period of 16 weeks. There is a gap in the information provided for the 6 weeks between the 12 and 16 marks. The graph or table also includes information on clinical decline.*
Image Of Figure 4: Cumulative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 05)
The text appears to be a graph or chart displaying the cumulative percentage of patients for two different treatments, Placebo and NAMENDA. The graph also includes a line graph representing the change from baseline in SIB (Severe Impairment Battery) scores. The x-axis shows the percentage, while the y-axis shows the change from baseline. There is not enough information to provide further details.*
Image Of Figure 5: Time Course Of The Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 06)
This is a graph showing the mean change from baseline in ADCS-ADL score in patients receiving either placebo/donepezil or Namenda/donepezil. The graph shows that patients who received Namenda/donepezil had less clinical decline compared to those who received placebo/donepezil. The graph also shows the weeks of treatment (0-18) and the mean score values.*
Image Of Figure 6: Cumulative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 07)
This text represents a graph showing the cumulative percentage of patients with Alzheimer's disease and the level of improvement on an activity of daily living scale (ADCS-ADL) after treatment with either placebo/donepezil or NAVENDA/donepezil. The graph indicates that a higher percentage of patients experience a positive change in their ADCS-ADL score after treatment with NAVENDA/donepezil compared to placebo/donepezil.*
Image Of Figure 7: Time Course Of The Change Graph (74ce605d B493 4b95 9d59 9253f81f4e20 08)
The text describes a clinical improvement in the SIB score, with a graph displaying the mean change from the baseline for a placebo and a medication called NAMENDA/Donep. The x-axis shows the weeks of treatment, and the y-axis displays the SIB score. There is also a line indicating clinical decline.*
Image Of Figure 8: Cumulative Percentage Graph (74ce605d B493 4b95 9d59 9253f81f4e20 09)
This is a graph that compares the cumulative percentage of patients and their SIB (Severe Impairment Battery) change from baseline when taking either a placebo and Donepezil combination or Namenda and Donepezil combination. The graph shows that the Namenda and Donepezil combination group has a better SIB change from baseline than the placebo and Donepezil group.*
Namenda 10mg (74ce605d B493 4b95 9d59 9253f81f4e20 10)
Namenda 5mg (74ce605d B493 4b95 9d59 9253f81f4e20 11)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
